Translational and Interdisciplinary Research

Discovery only matters when it reaches patients, and this session shows how to move from mechanism to measurable benefit—without losing rigor. We map a practical pathway that aligns molecular targets, imaging signatures, and functional outcomes with study designs that are credible to regulators and compelling to clinicians. You’ll learn how to turn multi-omics and advanced imaging into qualification-ready biomarkers; how to build disease models (organoids, chips, and animal lines) that actually predict human response; and how to select endpoints that survive peer review, payer evaluation, and post-market scrutiny. Translational & Interdisciplinary Research is where cornea meets data science, retina meets bioengineering, and clinics meet industry—organized around real implementation, not silos. If you’re scanning for the right Vision Conference to present a gene-editing, device, or digital biomarker program, this page clarifies the expectations: analytical validity, clinical validity, and clinical utility, each with sample evidence plans. We also cover human-factors engineering, quality by design, and manufacturing readiness for drugs, devices, and combinations, plus ethical frameworks for consent, return of results, and equitable enrollment. Teams will see how to integrate biostatistics with protocol design, use adaptive and platform trials, and capture real-world evidence to complement controlled studies. Finally, we explain how precision ophthalmology connects the dots—genotype, phenotype, environment, and behavior—to individualize risk prediction and therapy selection, ensuring that the right patient gets the right intervention at the right time, with burden and safety fully accounted for.